Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Akili (AKLI) has issued an announcement.
On May 29, 2024, Akili, Inc. (“the Company”) announced entering into a Merger Agreement with Virtual Therapeutics Corporation (“Parent”) and Alpha Merger Sub, Inc. (“Purchaser”), initiating a significant acquisition process. The transaction involves a cash tender offer for the Company’s common stock at $0.4340 per share, leading to a merger where the Company will become a wholly-owned subsidiary of Parent. The Company’s Board has unanimously approved the deal, recommending that stockholders accept the offer. The agreement includes customary representations, warranties, and covenants by both parties and outlines conditions for completion, including the tender of over 50% of the Company’s outstanding shares. The deal also sets forth termination rights and obligations, including a termination fee and an expense reimbursement under certain conditions.
For a thorough assessment of AKLI stock, go to TipRanks’ Stock Analysis page.
